首页> 外文期刊>Medicine. >Analysis of histological and immunological parameters of metastatic lymph nodes from colon cancer patients reveals that T-helper 1 type immune response is associated with improved overall survival
【24h】

Analysis of histological and immunological parameters of metastatic lymph nodes from colon cancer patients reveals that T-helper 1 type immune response is associated with improved overall survival

机译:来自结肠癌患者的转移性淋巴结的组织学和免疫参数的分析表明,T-辅助1型免疫应答与改善的整体存活相关

获取原文
获取外文期刊封面目录资料

摘要

Lymph node (LN) involvement in colonic carcinoma (CC) is a grave prognostic sign and mandates the addition of adjuvant treatment. However, in light of the histological variability and outcomes observed, we hypothesized that patients with LN metastases (LNM) comprise different subgroups. We retrospectively analyzed the histological sections of 82 patients with CC and LNM. We studied various histological parameters (such as tumor grade, desmoplasia, and preservation of LN architecture) as well as the prevalence of specific peritumoral immune cells (CD8+, CD20+, T-bet+, and GATA-3+). We correlated the histological and immunological data to patient outcome. Tumor grade was a significant prognostic factor even in patients with LNM. So was the number of LN involved (N1/N2 stage). From the morphological parameters tested (LN extracapsular invasion, desmoplasia in LN, LN architecture preservation, and mode of metastases distribution), none was found to be significantly associated with overall survival (OS). The mean OS of CD8+ low patients was 66.6?±?6.25 versus 71.4?±?5.1 months for CD8+ high patients (P?=?0.79). However, T-helper (Th) 1 immune response skewing (measured by Th1/Th2 ratio >1) was significantly associated with improved OS. For patients with low ratio, the median OS was 35.5?±?5 versus 83.5 months for patients with high Th1/Th2 ratio (P?=?0.001). The histological presentation of LNM does not entail specific prognostic information. However, the finding of Th1 immune response in LN signifies a protective immune response. Future studies should be carried to verify this marker and develop a strategy that augments this immune response during subsequent adjuvant treatment.
机译:淋巴结(LN)参与结肠癌(CC)是一种严重的预后征兆,并授权添加佐剂治疗。然而,鉴于观察到的组织学变异性和结果,我们假设具有LN转移(LNM)的患者包括不同的亚组。我们回顾性地分析了82例CC和LNM患者的组织学部分。我们研究了各种组织学参数(例如肿瘤级,脱落和LN架构的保存)以及特异性腹部免疫细胞的患病率(CD8 + ,CD20 + , t-bet + 和gata-3 + )。我们将组织学和免疫数据与患者结果相关联。肿瘤等级即使在LNM患者中也是显着的预后因子。所涉及的LN数量(N1 / N2阶段)。从测试的形态学参数(LN倍增侵袭,LN,LN建筑保存和转移模式分布),没有发现与整体存活率有显着相关(OS)。 CD8 + 低患者的平均OS为66.6?±6.2.2.25与71.4?±5.1个月为CD8 + 高患者(p?= 0.79)。然而,T-辅助(TH)1免疫应答偏移(由TH2比率> 1测量)与改善的OS显着相关。对于低比例的患者,中位数OS为35.5?±5,对于高TH / TH2比率的患者(P?= 0.001)。 LNM的组织学呈现不需要特定的预后信息。然而,LN中Th1免疫应答的发现意味着保护性免疫应答。应携带未来的研究以验证此标记,并制定一种在随后的佐剂治疗期间增加这种免疫应答的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号